Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Prophylactic Skin Toxicity Therapy in Glioblastoma Patients Treated With TTFields
NCT04469075Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2020
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of clindamycin, triamcinolone acetonide in Skin Toxicity, sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2020; status: active, not recruiting.
02
Drugs
clindamycintriamcinolone acetonide
03
Conditions
Skin Toxicity
Beyond the preview
Go deeper on NCT04469075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469075.